title: Hemodynamic and neurohormonal effects of flosequinan in patients with heart failure.
abstract: In a double-blind, placebo-controlled study, the central and peripheral hemodynamic effects of 100 mg oral flosequinan and the impact of this drug on neurohormonal activation were noninvasively evaluated in 18 patients with congestive heart failure, after the first administration and after 10 days of treatment. No significant hemodynamic and neurohormonal changes were observed after acute administration. After 10 days, flosequinan produced central and peripheral hemodynamic improvement characterized by an increase in left ventricular circumferential fiber shortening velocity (+12%), a decrease in total systemic resistance (-36%), and an increase in leg blood flow (+37%). No significant changes were observed in heart rate and arterial pressure in patients receiving flosequinan, though a slight increase in heart rate (+17%) was recorded. Despite these favorable hemodynamic effects, flosequinan significantly increased plasma norepinephrine (+38%) and plasma renin activity (+13%) after 10 days of treatment. Thus, the beneficial central and peripheral hemodynamic effects of flosequinan are accompanied by activation of the sympathetic and reninangiotensin systems. This might be related to the unfavorable effects of the drug on survival in patients with heart failure.
authors.affiliation: Cardiology Department, Pitié-Salpétrière Hospital, Paris, France.
authors.forename: R
authors.initials: R
authors.lastname: Isnard
authors.forename: P
authors.initials: P
authors.lastname: Lechat
authors.forename: F
authors.initials: F
authors.lastname: Pousset
authors.forename: A
authors.initials: A
authors.lastname: Carayon
authors.forename: H
authors.initials: H
authors.lastname: Kalotka
authors.forename: H
authors.initials: H
authors.lastname: Chikr
authors.forename: J
authors.initials: J
authors.lastname: Salloum
authors.forename: D
authors.initials: D
authors.lastname: Thomas
authors.forename: M
authors.initials: M
authors.lastname: Komajda
mesh_terms: D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood; D011804:Quinolines / Q000494:pharmacology*; D012083:Renin / Q000097:blood; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: D011804:Quinolines; D014665:Vasodilator Agents; C047316:flosequinan; D012083:Renin; D009638:Norepinephrine